ATTR-CM (transthyretin amyloid cardiomyopathy) is a progressive heart condition that causes shortness of breath, fatigue, swelling in the legs, and exercise intolerance. It happens when a protein called transthyretin, normally made by the liver, becomes unstable, breaks apart, and refolds into abnormal fibers that deposit in the heart muscle, making the walls stiff and thick. What makes ATTR-CM tricky is that many of its symptoms look like ordinary heart failure, and the earliest warning signs often show up outside the heart entirely, sometimes a decade before a cardiac diagnosis.
How ATTR-CM Develops
Transthyretin is a protein that circulates in your blood and helps transport thyroid hormone and vitamin A. In ATTR-CM, this protein becomes unstable and breaks down from its normal four-part structure into individual units. Those units misfold, clump together, and form stiff fibers called amyloid that gradually infiltrate the heart muscle. As these deposits build up in the walls of the heart, the muscle becomes rigid and struggles to fill with blood properly between beats.
There are two forms. The hereditary form (hATTR-CM) is caused by a gene mutation and can appear as early as the 50s or 60s, sometimes with significant nerve involvement alongside heart problems. The wild-type form (wtATTR-CM) has no genetic cause and typically affects men over 70. Both forms produce similar cardiac symptoms, but the hereditary form is more likely to include numbness, tingling, and problems with automatic body functions like blood pressure regulation and digestion.
Heart Failure Symptoms
The core symptoms of ATTR-CM are the same ones seen in heart failure generally, which is one reason the condition is so often missed. These include:
- Shortness of breath during activity, while lying flat, or waking you from sleep
- Fatigue and exercise intolerance that progressively limits daily activities
- Swelling in the legs, ankles, and feet
- Dizziness or fainting, particularly on standing
- Palpitations or irregular heartbeat
Because amyloid deposits stiffen the heart rather than weakening the pump itself, many patients have what’s called heart failure with preserved ejection fraction, where the heart still squeezes normally but can’t relax and fill. A Spanish study screening over 400 patients with this type of heart failure found that nearly 17% actually had underlying ATTR-CM. That’s a striking number, and it suggests many people living with a generic heart failure diagnosis may have this specific, treatable cause.
Right-sided heart failure signs are particularly common in ATTR-CM. This means fluid backs up into the abdomen and liver rather than just the lungs, leading to a swollen belly (ascites), an enlarged liver, and persistent lower leg edema that may respond poorly to standard water pills.
Early Warning Signs Outside the Heart
Some of the most important ATTR-CM symptoms have nothing to do with the heart, and they often appear years before any cardiac problems become obvious. The same misfolded protein deposits in tendons, ligaments, and nerves throughout the body.
Carpal tunnel syndrome is present in roughly 50% of patients diagnosed with ATTR-CM, and the symptoms typically show up 5 to 10 years before the heart is affected. Bilateral carpal tunnel, meaning both wrists are involved, is especially suspicious. One screening study found that among men over 70 who had previously undergone surgery for bilateral carpal tunnel, 20% had early-stage ATTR-CM.
Lumbar spinal stenosis is another red flag. Amyloid deposits accumulate in the spinal ligaments, narrowing the spinal canal and causing back pain, leg weakness, or difficulty walking. Studies examining tissue removed during spinal stenosis surgery have found high rates of amyloid deposits, and about 15% of those patients with significant deposits went on to be diagnosed with ATTR-CM within six years.
Spontaneous biceps tendon rupture, where the tendon tears without a major injury, is another clue that sometimes appears in the medical history of people later diagnosed with ATTR-CM. Any combination of these soft tissue problems, particularly in an older man, should raise suspicion.
Nerve and Autonomic Symptoms
The hereditary form of ATTR-CM frequently involves the nervous system. Peripheral neuropathy causes numbness, tingling, or burning pain that usually starts in the feet and moves upward over time. This can make walking difficult and affect balance.
Autonomic neuropathy disrupts the body’s automatic functions. Common effects include a sudden drop in blood pressure when standing (causing dizziness or fainting), digestive problems like feeling full after just a few bites, chronic diarrhea or constipation, nausea, and difficulty swallowing. These symptoms can be debilitating on their own and are easily attributed to aging or other conditions, which adds to the diagnostic delay.
Why Diagnosis Takes So Long
ATTR-CM is significantly underdiagnosed. The average time from first symptoms to a confirmed diagnosis is about 4 years. From the point a patient is first recognized as having heart failure, the median delay is still roughly 16 months, and more than 25% of patients wait over 3 years after their initial heart failure diagnosis before ATTR-CM is identified.
The delay matters because untreated survival is limited. Patients with the most common hereditary mutation in the United States (Val122Ile, which is carried by roughly 3-4% of Black Americans) have a median survival of about 2.5 years from diagnosis without treatment. For wild-type ATTR-CM, median survival without treatment is approximately 3.6 years.
Treatment with a protein-stabilizing medication changed these numbers substantially. In a long-term study, patients who received continuous treatment had a median survival of 67 months (over 5.5 years), compared to roughly 35 months in those who did not receive the drug or started it later. Earlier diagnosis means earlier treatment and meaningfully longer survival.
How ATTR-CM Is Confirmed
If your doctor suspects ATTR-CM, a specialized imaging test called a cardiac PYP scan (or bone scintigraphy) can confirm it without a biopsy in most cases. A radioactive tracer is injected and taken up by amyloid deposits in the heart. Results are graded on a scale from 0 to 3: grade 0 is negative, grade 1 is unclear, and grades 2 or 3 are considered positive for ATTR amyloidosis. A blood test is also done to rule out a related but different type of amyloidosis (AL amyloidosis) that requires different treatment.
Genetic testing follows a positive scan to determine whether the condition is hereditary or wild-type, since this affects both the patient’s treatment plan and whether family members should be screened.
Symptoms That Should Prompt Screening
The combination of heart failure symptoms with any of the following should raise a red flag for ATTR-CM: bilateral carpal tunnel syndrome (especially if surgery was needed), spinal stenosis, unexplained thickening of the heart wall on an echocardiogram, atrial fibrillation that doesn’t respond well to treatment, or a history of spontaneous tendon rupture. Peripheral neuropathy or autonomic symptoms alongside heart failure add further suspicion, particularly in someone with a family history of the condition or African American heritage. Recognizing the pattern of symptoms, rather than any single one in isolation, is what leads to a timely diagnosis.